Immunization with recombinant gp160 prolongs the survival of HIV-1 transgenic mice

AIDS Res Hum Retroviruses. 1993 Oct;9(10):979-83. doi: 10.1089/aid.1993.9.979.


A strain of mouse transgenic for the env gene of the HIV-1 virus was used to study the immunogenicity of a gp160-derived vaccine (the protein encoded by the HIV env gene) and its effect on disease progression. Untreated transgenic mice frequently developed a rapidly progressive renal disease similar to that affecting approximately 10% of HIV-infected humans. When transgenic mice were immunized with recombinant purified gp160, their edema, proteinuria, and serum BUN levels were substantially reduced and their survival prolonged (p < 0.01). The increased longevity of immunized transgenic mice correlated with the production of IgG antibodies reactive with gp160.

MeSH terms

  • AIDS Vaccines / therapeutic use*
  • Acquired Immunodeficiency Syndrome / prevention & control*
  • Animals
  • Blotting, Western
  • Enzyme-Linked Immunosorbent Assay
  • Gene Products, env / immunology*
  • HIV Antibodies / blood
  • HIV Envelope Protein gp160
  • HIV-1 / genetics
  • Immunization*
  • Mice
  • Mice, Transgenic
  • Nephrotic Syndrome / prevention & control*
  • Protein Precursors / immunology*
  • Proviruses / genetics
  • Survival Analysis
  • Vaccines, Synthetic / therapeutic use*


  • AIDS Vaccines
  • Gene Products, env
  • HIV Antibodies
  • HIV Envelope Protein gp160
  • Protein Precursors
  • Vaccines, Synthetic